Neoantigen cancer vaccines are usually tumor-specific vaccines based on the neoantigens identified from an individual. They are delivered via cell, protein, or the nucleic acid-based platform with the ultimate aim of getting a strong antitumor response. The neoantigen cancer vaccines are further segmented into personalized and off-the-shelf neovaccines based on the target neoantigen.
The biggest concerns with the neovaccines are their cost, limited efficacy, and the long amounts of time they take to create, but as technology improves, these issues will be resolved.
The genetic instability of tumor cells often leads to a large number of mutations, which in turn can produce tumor-specific antigens commonly known as neoantigens. Neoantigens are extremely immunogenic and are not present in normal tissues.
Neoantigens have the potential to be the new targets for cancer tumor immunotherapy. Neo antigens can activate CD8+ and CD4+ T cells to generate an immune response. (CD stands for Cluster of Differentiation).
Development in bioinformatics technology has enabled the acceleration of the identification of neoantigens.
Presently, multiple clinical trials have established the safety and effectiveness of these neoantigen cancer vaccines. Further development in sequencing technologies and bioinformatics algorithms will increase the application of neoantigen vaccines in the future.
Personalized cancer vaccines target neoantigens that are unique to an individual’s tumor profile. In recent years, neoantigen-based personalized vaccines have been demonstrated to be immunogenic, safe, and effective in patients with glioblastoma and melanoma.
Personalized cancer vaccines target neoantigens that are unique to an individual’s tumor profile. In recent years, neoantigen-based personalized vaccines have been demonstrated to be immunogenic, safe, and effective in patients with glioblastoma and melanoma.
|
Implications of Personalized Cancer Vaccines |
|
|
Pros |
Cons |
|
PCVs hold an immense potential to be reformulated in cases of relapse setting to identify new mutations. |
This overall process of PCV development is time-consuming and expensive due to the hard scalability of PCVs and associated de novo manufacturing/synthesis steps after a patient’s DNA is being sequenced. |
|
PCVs address the issue of clonal heterogeneity by the inclusion of formulations that include several epitopes. |
The effectiveness of a de novo synthesized neoantigen is hard to predict. In addition to this, the regulatory supervision of the admission and manufacturing requires attention, which further hampers the overall PCV development process. |
The global neoantigen cancer vaccine industry analysis by BIS Research projects the market to grow at a significant CAGR of 77.73% during the forecast period 2024-2031. The neoantigen cancer vaccine market is expected to generate $35.5 million in revenue in 2024 due to the anticipated launch of the world’s first neoantigen vaccine.
1. Rising prevalence of cancer
2. Increasing adoption of personalized treatment and medicines
3. Funding to execute research and development
4. Innovations by key players
1. High cost of personalized cancer vaccines
2. Hurdles in clinical development and optimization processes
3. Manufacturing complications
4. Uncertain reimbursement scenario
5. Payer uncertainty and outcome-based pricing
6. High capital requirement for research and development
BIS Research’s healthcare team provides valuable and actionable information to its clients on trends and technologies disrupting the different segments of the healthcare industry
One of the key highlights of our market intelligence solution is the Deep Tech M-A-P™ approach. M-A-P™ includes Market, Application, and Product.
Clients at BIS Research can choose from various services, including syndicated research reports, custom research, expert consultations, individually or in any combination of the three based on their requirements.
1. Estimated global neoantigen cancer vaccine market size
2. CAGR of the market for the forecast period 2024-2031
3. Key trends, market drivers, and opportunities in the global neoantigen cancer vaccine market
4. Challenges in the global neoantigen cancer vaccine market
5. Revenue forecast and market coverage of the industry
6. Revenue of each segment of the global neoantigen cancer vaccine market
7. Top stakeholders and their roles in the global neoantigen cancer vaccine market
8. Underlying structures resulting in the emerging trends within the global neoantigen cancer vaccine market
9. Impact of COVID-19 on global neoantigen cancer vaccine market
10. Key development strategies of major players in order to sustain competition and their offerings
11. Regulatory implications in developed and developing regions for neoantigen cancer vaccines
12. Potential entry barriers for companies willing to enter a particular region
13. Companies expected to be highly disruptive in the future and reasons for the same
Read more about the Global Neoantigen Cancer Vaccine Market in our report. Request a sample here: https://bisresearch.com/requestsample?id=1254&type=download
Interested to know which new technology is emerging in your industry vertical? Get the latest market insights and studies from BIS Research. Connect with us at hello@bisresearch.com to learn more.